Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Entera Bio Ltd (ENTX)

Entera Bio Ltd (ENTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,276
  • Shares Outstanding, K 35,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,890 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.62
  • Price/Sales 669.80
  • Price/Cash Flow N/A
  • Price/Book 10.26

Options Overview Details

View History
  • Implied Volatility 595.44% ( +26.67%)
  • Historical Volatility 79.48%
  • IV Percentile 90%
  • IV Rank 50.41%
  • IV High 1,123.67% on 02/19/25
  • IV Low 58.48% on 08/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 375
  • Open Int (30-Day) 358

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7800 +8.96%
on 03/10/25
2.4900 -22.11%
on 02/18/25
-0.4905 (-20.19%)
since 02/14/25
3-Month
1.7800 +8.96%
on 03/10/25
2.7900 -30.48%
on 01/07/25
-0.2805 (-12.64%)
since 12/17/24
52-Week
1.3000 +49.19%
on 03/20/24
3.3500 -42.10%
on 04/12/24
+0.5695 (+41.57%)
since 03/15/24

Most Recent Stories

More News
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

OPK : 1.7550 (+0.86%)
ENTX : 1.9395 (+3.16%)
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

ENTX : 1.9395 (+3.16%)
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

ENTX : 1.9395 (+3.16%)
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic...

ENTX : 1.9395 (+3.16%)
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and...

ENTX : 1.9395 (+3.16%)
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is...

ENTX : 1.9395 (+3.16%)
Entera Bio Reports Financial Results for the Year Ended December 31, 2021

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral...

ENTX : 1.9395 (+3.16%)
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule...

ENTX : 1.9395 (+3.16%)
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒...

ENTX : 1.9395 (+3.16%)
Entera Bio Reports Third Quarter 2021 Financial Results

‒ Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3...

ENTX : 1.9395 (+3.16%)

Business Summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an...

See More

Key Turning Points

3rd Resistance Point 2.0933
2nd Resistance Point 2.0467
1st Resistance Point 1.9633
Last Price 1.9395
1st Support Level 1.8333
2nd Support Level 1.7867
3rd Support Level 1.7033

See More

52-Week High 3.3500
Fibonacci 61.8% 2.5669
Fibonacci 50% 2.3250
Fibonacci 38.2% 2.0831
Last Price 1.9395
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar